This study tests a new drug called 212Pb-DOTAMTATE that delivers radiation directly to neuroendocrine tumor cells. It includes 69 adults whose tumors have a specific marker (somatostatin receptor) and have worsened after standard treatments. The goal is to see if the drug can shr…
Phase: PHASE2 • Sponsor: Orano Med LLC • Aim: Disease control
Last updated May 11, 2026 20:49 UTC